NVAX - Novavax, Inc.
| Previous Close | 1.47 |
| Open | 1.60 |
| Bid | 1.59 x 21500 |
| Ask | 1.60 x 2900 |
| Day's Range | 1.55 - 1.70 |
| 52 Week Range | 0.96 - 2.75 |
| Volume | 9,211,120 |
| Avg. Volume | 3,787,429 |
| Market Cap | 608.321M |
| Beta | 3.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.86 |
- MarketWatch•2 hours ago
Novavax's stock soars after J.P. Morgan swings to bullish from bearish ahead of trial results
Shares of Novavax Inc. soared 12% in premarket trade Friday, after J.P. Morgan analyst Eric Joseph swung to bullish from bearish, citing a favorable risk-reward investment profile ahead of pivotal trial data on its RSV treatment for infants, due out in the first quarter of 2019. Joseph raised his rating two notches to overweight from underweight. He said the shares have already pulled back sharply from recent highs on "receding expectations" regarding the trial outcome. As a result, he sees 50% to over 100% potential upside in the stock after the results, and about an 80% downside risk on a trial failure, but that is viewed as a "less likely" event. "Looking beyond the phase 3 readout, we believe positive PREPARE data would support broader development to additional at-risk populations and their inclusion in the model (pediatric patients under 2yo)," Joseph wrote in a note to clients. The stock had tumbled 39% from the Feb. 20 17-month closing high of $2.42. Over the same time, the iShares Nasdaq Biotechnology ETF has climbed 9.2% and the S&P 500 has advanced 7.9%.
- Motley Fool•9 days ago
3 Stocks That Could Double Your Money
There are no guarantees, of course, but these stocks appear to be reasonably good bets for doubling in the not-too-distant future.
- Motley Fool•11 days ago
Here's Why Novavax, Inc. Jumped 22.8% in August
Clinical trial progress has investors excited about the vaccine company's future.
- Motley Fool•11 days ago
Where Will Novavax, Inc. Be in 1 Year?
Novavax's next clinical catalyst could be a game changer for the company.
- Motley Fool•17 days ago
Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
Institutional investors are selling these big names. Here's why you may want to do the opposite.
- GlobeNewswire•21 days ago
Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FS ...
- GlobeNewswire•24 days ago
Novavax to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 28, 2018-- Novavax, Inc. today announced that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13 th Annual Biotech Conference in September.. ...
- Zacks•25 days ago
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•29 days ago
Edited Transcript of NVAX earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 Novavax Inc Earnings Call
- Market Realist•last month
Analyzing Novavax’s Financial Performance
Novavax (NVAX) generated revenue of $10.77 million in the second quarter compared to $6.73 million in the comparable period in 2017. The increase in the company’s revenue resulted from a $2 million increase in the Bill and Melinda Gates Foundation grant revenue due to higher enrolment in Novavax’s Prepare trial and an additional $2 million from increased activities from Novavax AB. The general and administrative expenses incurred by Novavax decreased from $8.94 million in the second quarter of 2017 to $8.22 million in the second quarter of 2018.
- Market Realist•last month
Gauging Analysts’ Expectations for Novavax and Peers in August
Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.
- Motley Fool•last month
5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them
Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.
- Motley Fool•last month
Why Novavax, Inc. Shares Are Soaring Today
The clinical-stage biotech provided good news for two key vaccines in its pipeline.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Novavax and INSYS Therapeutics
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
- Zacks•last month
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and 4.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Novavax: 2Q Earnings Snapshot
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 12 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- GlobeNewswire•last month
Novavax Reports Second Quarter 2018 Financial Results
Novavax Delivers on Key Milestones Supporting its 2018 Objectives. Company to Host Conference Call Today at 4:30 pm ET. GAITHERSBURG, Md., Aug. 08, 2018-- Novavax, Inc. today announced its financial results ...
- ACCESSWIRE•last month
Novavax, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Novavax, Inc. (NASDAQ: NVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...
- GlobeNewswire•2 months ago
Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 8, 2018
GAITHERSBURG, Md., Aug. 01, 2018-- Novavax, Inc. today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August ...
Motley Fool•2 months agoHow to Invest in Clinical-Stage Biotechs Without Losing Money
Clinical-stage biotechs can wreak havoc on your portfolio. Here's one approach that can limit the potential damage while still allowing you to take a long-term approach to capital appreciation.
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for At Home Group, Royal Bank Of Canada, Curis, Novavax, HNI, and Freshpet — Fundamental Analysis, Key Performance Indications
NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of At ...
- Investopedia•2 months ago
Top 3 Healthcare Penny Stocks for 2018
The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.
Motley Fool•2 months agoBetter Buy: Novavax, Inc. vs. Pfizer
Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.
- Motley Fool•2 months ago
Why Novavax Stock Buckled in June
Novavax's stock got blasted by geopolitical headwinds last month, but that doesn't mean it's now a bargain.
